Budapest, Hungary

Ákos Putics

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ákos Putics: Innovator in Glycoprotein Modification

Introduction

Ákos Putics is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of biotechnology, particularly in the area of glycoprotein production. His innovative methods have the potential to enhance the efficacy of therapeutic proteins.

Latest Patents

Ákos Putics holds a patent for a method aimed at modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture. The patent, which is titled "Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture," describes a process that involves culturing eukaryotic cells expressing the recombinant glycoprotein in a specially supplemented cell culture medium. This medium includes fucose, manganese, and taurine, which together modify the glycosylation profile of the produced glycoprotein to more closely resemble that of a reference glycoprotein compared to cultures without such supplementation. He has 1 patent to his name.

Career Highlights

Ákos Putics is currently employed at Richter Gedeon Nyrt., a prominent pharmaceutical company in Hungary. His work focuses on advancing biopharmaceutical technologies and improving the production processes of therapeutic proteins. His expertise in glycoprotein modification has positioned him as a valuable asset in the field.

Collaborations

Throughout his career, Ákos has collaborated with several talented individuals, including László Párta and Tibor Balogh. These collaborations have fostered innovation and contributed to the development of new methodologies in biotechnology.

Conclusion

Ákos Putics is a distinguished inventor whose work in glycoprotein modification is paving the way for advancements in biopharmaceuticals. His contributions are essential for the future of therapeutic protein production.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…